243 related articles for article (PubMed ID: 29576407)
1. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
[TBL] [Abstract][Full Text] [Related]
2. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V
J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865
[TBL] [Abstract][Full Text] [Related]
4. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E; Benitez-Montanez J; Tagliamento M; Parisi F; Gorria T; Garcia-Campelo R; Dempsey N; Pinato DJ; Reyes R; Albarrán-Artahona V; Dall'Olio F; Soldato D; Hendriks L; Nana FA; Tonneau M; Lopez-Castro R; Nadal E; Kazandjian S; Muanza T; Blanc-Durand F; Fabre E; Castro N; Arasanz H; Rochand A; Besse B; Routy B; Mezquita L
Lung Cancer; 2023 Apr; 178():116-122. PubMed ID: 36812760
[TBL] [Abstract][Full Text] [Related]
5. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
7. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
Alholm Z; Monk BJ; Ting J; Pulgar S; Boyd M; Sudharshan L; Bains S; Nicacio L; Coleman RL
Gynecol Oncol; 2021 May; 161(2):422-428. PubMed ID: 33741208
[TBL] [Abstract][Full Text] [Related]
9. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
10. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
11. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.
Shire NJ; Klein AB; Golozar A; Collins JM; Fraeman KH; Nordstrom BL; McEwen R; Hembrough T; Rizvi NA
PLoS One; 2020; 15(9):e0238358. PubMed ID: 32881920
[TBL] [Abstract][Full Text] [Related]
12. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
[TBL] [Abstract][Full Text] [Related]
13. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
Waterhouse D; Lam J; Betts KA; Yin L; Gao S; Yuan Y; Hartman J; Rao S; Lubinga S; Stenehjem D
Lung Cancer; 2021 Jun; 156():41-49. PubMed ID: 33894493
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting.
Simeone JC; Nordstrom BL; Patel K; Klein AB
Future Oncol; 2019 Oct; 15(30):3491-3502. PubMed ID: 31497994
[No Abstract] [Full Text] [Related]
16. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
Shao C; He J; Kachroo S; Jin F
Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
[TBL] [Abstract][Full Text] [Related]
17. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
[No Abstract] [Full Text] [Related]
18. RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain.
Badiola LB; Milagro NL; Lavín DC; Peraita SL; Ibarbia MA; Kareaga MM; Fernández Del Rivero TP; Otero DSP; López VA; Fernández CÁ; Emborujo AL; Arnaiz IG; Rodríguez RF; Sagastibeltza N; Duran I;
Semin Oncol; 2024 Mar; ():. PubMed ID: 38604897
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
[TBL] [Abstract][Full Text] [Related]
20. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
Sacher AG; Le LW; Lau A; Earle CC; Leighl NB
Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
